Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tafasitamab
- Development stage
- Approved
- Lead developer
- Incyte
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Tafasitamab is a humanized, Fc-modified monoclonal antibody that targets the CD19 antigen expressed on the surface of pre-B and mature B lymphocytes, as well as several B-cell malignancies including diffuse large B-cell lymphoma (DLBCL). Upon binding to CD19, tafasitamab mediates B-cell lysis through direct induction of apoptosis and immune effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). The Fc region of tafasitamab is engineered for enhanced affinity to Fcγ receptors, increasing its potency in engaging immune effector cells like natural killer cells and γδ T cells. Tafasitamab is approved in combination with lenalidomide for adults with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplant[2][4][5][6][8].
- Brand names
- MonjuviMinjuvi
- Other names
- tafasitamab-cxix
02
Targets
Beyond the preview
Go deeper on tafasitamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tafasitamab.